Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Neuropathology Market

ID: MRFR/Pharma/18440-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Neuropathology Market Research Report By Diagnostic Test (Biopsy, Body fluids, Peripheral blood smears, Tissue resections, Others), By Application (Cerebral hypoxia and stroke, Perinatal disorders, CNS infections, Demyelinative diseases, Brain tumors, Neurodegenerative diseases, Inherited metabolic disorders, Peripheral neuropathy, Myopathology) and By End User (Hospitals, Clinics, Research centers, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Neuropathology Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Diagnostic Test (USD Million)
  49.     4.1.1 biopsy
  50.     4.1.2 body fluids
  51.     4.1.3 peripheral blood smears
  52.     4.1.4 tissue resections
  53.     4.1.5 others
  54.   4.2 Construction, BY Application (USD Million)
  55.     4.2.1 cerebral hypoxia and stroke
  56.     4.2.2 perinatal disorders
  57.     4.2.3 CNS infections
  58.     4.2.4 demyelinative diseases
  59.     4.2.5 brain tumors
  60.     4.2.6 neurodegenerative diseases
  61.     4.2.7 inherited metabolic disorders
  62.     4.2.8 peripheral neuropathy
  63.     4.2.9 myopathology
  64.   4.3 Construction, BY End-User (USD Million)
  65.     4.3.1 hospitals
  66.     4.3.2 clinics
  67.     4.3.3 research centers
  68.     4.3.4 others
  69. 5 SECTION V: COMPETITIVE ANALYSIS
  70.   5.1 Competitive Landscape
  71.     5.1.1 Overview
  72.     5.1.2 Competitive Analysis
  73.     5.1.3 Market share Analysis
  74.     5.1.4 Major Growth Strategy in the Construction
  75.     5.1.5 Competitive Benchmarking
  76.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  77.     5.1.7 Key developments and growth strategies
  78.       5.1.7.1 New Product Launch/Service Deployment
  79.       5.1.7.2 Merger & Acquisitions
  80.       5.1.7.3 Joint Ventures
  81.     5.1.8 Major Players Financial Matrix
  82.       5.1.8.1 Sales and Operating Income
  83.       5.1.8.2 Major Players R&D Expenditure. 2023
  84.   5.2 Company Profiles
  85.     5.2.1 Roche (CH)
  86.       5.2.1.1 Financial Overview
  87.       5.2.1.2 Products Offered
  88.       5.2.1.3 Key Developments
  89.       5.2.1.4 SWOT Analysis
  90.       5.2.1.5 Key Strategies
  91.     5.2.2 Thermo Fisher Scientific (US)
  92.       5.2.2.1 Financial Overview
  93.       5.2.2.2 Products Offered
  94.       5.2.2.3 Key Developments
  95.       5.2.2.4 SWOT Analysis
  96.       5.2.2.5 Key Strategies
  97.     5.2.3 Abbott Laboratories (US)
  98.       5.2.3.1 Financial Overview
  99.       5.2.3.2 Products Offered
  100.       5.2.3.3 Key Developments
  101.       5.2.3.4 SWOT Analysis
  102.       5.2.3.5 Key Strategies
  103.     5.2.4 Siemens Healthineers (DE)
  104.       5.2.4.1 Financial Overview
  105.       5.2.4.2 Products Offered
  106.       5.2.4.3 Key Developments
  107.       5.2.4.4 SWOT Analysis
  108.       5.2.4.5 Key Strategies
  109.     5.2.5 Philips (NL)
  110.       5.2.5.1 Financial Overview
  111.       5.2.5.2 Products Offered
  112.       5.2.5.3 Key Developments
  113.       5.2.5.4 SWOT Analysis
  114.       5.2.5.5 Key Strategies
  115.     5.2.6 GE Healthcare (US)
  116.       5.2.6.1 Financial Overview
  117.       5.2.6.2 Products Offered
  118.       5.2.6.3 Key Developments
  119.       5.2.6.4 SWOT Analysis
  120.       5.2.6.5 Key Strategies
  121.     5.2.7 Bristol-Myers Squibb (US)
  122.       5.2.7.1 Financial Overview
  123.       5.2.7.2 Products Offered
  124.       5.2.7.3 Key Developments
  125.       5.2.7.4 SWOT Analysis
  126.       5.2.7.5 Key Strategies
  127.     5.2.8 Merck KGaA (DE)
  128.       5.2.8.1 Financial Overview
  129.       5.2.8.2 Products Offered
  130.       5.2.8.3 Key Developments
  131.       5.2.8.4 SWOT Analysis
  132.       5.2.8.5 Key Strategies
  133.     5.2.9 Agilent Technologies (US)
  134.       5.2.9.1 Financial Overview
  135.       5.2.9.2 Products Offered
  136.       5.2.9.3 Key Developments
  137.       5.2.9.4 SWOT Analysis
  138.       5.2.9.5 Key Strategies
  139.   5.3 Appendix
  140.     5.3.1 References
  141.     5.3.2 Related Reports
  142. 6 LIST OF FIGURES
  143.   6.1 MARKET SYNOPSIS
  144.   6.2 US MARKET ANALYSIS BY DIAGNOSTIC TEST
  145.   6.3 US MARKET ANALYSIS BY APPLICATION
  146.   6.4 US MARKET ANALYSIS BY END-USER
  147.   6.5 KEY BUYING CRITERIA OF CONSTRUCTION
  148.   6.6 RESEARCH PROCESS OF MRFR
  149.   6.7 DRO ANALYSIS OF CONSTRUCTION
  150.   6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  151.   6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  152.   6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
  153.   6.11 CONSTRUCTION, BY DIAGNOSTIC TEST, 2024 (% SHARE)
  154.   6.12 CONSTRUCTION, BY DIAGNOSTIC TEST, 2024 TO 2035 (USD Million)
  155.   6.13 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
  156.   6.14 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
  157.   6.15 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
  158.   6.16 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
  159.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  160. 7 LIST OF TABLES
  161.   7.1 LIST OF ASSUMPTIONS
  162.     7.1.1
  163.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  164.     7.2.1 BY DIAGNOSTIC TEST, 2025-2035 (USD Million)
  165.     7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  166.     7.2.3 BY END-USER, 2025-2035 (USD Million)
  167.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  168.     7.3.1
  169.   7.4 ACQUISITION/PARTNERSHIP
  170.     7.4.1

US Construction Market Segmentation

Construction By Diagnostic Test (USD Million, 2025-2035)

  • biopsy
  • body fluids
  • peripheral blood smears
  • tissue resections
  • others

Construction By Application (USD Million, 2025-2035)

  • cerebral hypoxia and stroke
  • perinatal disorders
  • CNS infections
  • demyelinative diseases
  • brain tumors
  • neurodegenerative diseases
  • inherited metabolic disorders
  • peripheral neuropathy
  • myopathology

Construction By End-User (USD Million, 2025-2035)

  • hospitals
  • clinics
  • research centers
  • others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions